114 related articles for article (PubMed ID: 11882007)
1. Design and synthesis of a novel L-dopa-entacapone codrug.
Leppänen J; Huuskonen J; Nevalainen T; Gynther J; Taipale H; Järvinen T
J Med Chem; 2002 Mar; 45(6):1379-82. PubMed ID: 11882007
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
4. Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.
Vemić A; Jančić Stojanović B; Stamenković I; Malenović A
J Pharm Biomed Anal; 2013 Apr; 77():9-15. PubMed ID: 23354116
[TBL] [Abstract][Full Text] [Related]
5. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa.
Cingolani GM; Di Stefano A; Mosciatti B; Napolitani F; Giorgioni G; Ricciutelli M; Claudi F
Bioorg Med Chem Lett; 2000 Jun; 10(12):1385-8. PubMed ID: 10890170
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö PT; Järvinen T
J Pharm Pharmacol; 2001 Nov; 53(11):1489-98. PubMed ID: 11732751
[TBL] [Abstract][Full Text] [Related]
9. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
[TBL] [Abstract][Full Text] [Related]
10. LC/MS/MS study for identification of entacapone degradation product obtained by photodegradation kinetics.
Paim CS; Palma EC; Malesuik MD; Steppe M
J AOAC Int; 2010; 93(6):1856-61. PubMed ID: 21313812
[TBL] [Abstract][Full Text] [Related]
11. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
Qandil AM; Rezigue MM; Tashtoush BM
Eur J Pharm Sci; 2011 Jun; 43(3):99-108. PubMed ID: 21466853
[TBL] [Abstract][Full Text] [Related]
13. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Brusa L; Bassi A; Lunardi G; Fedele E; Peppe A; Stefani A; Pasqualetti P; Stanzione P; Pierantozzi M
Eur J Neurol; 2004 Sep; 11(9):593-606. PubMed ID: 15379738
[TBL] [Abstract][Full Text] [Related]
14. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
15. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
[TBL] [Abstract][Full Text] [Related]
16. A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: synthesis and in vitro evaluation.
Abu Zanat FZ; Qandil AM; Tashtoush BM
Drug Dev Ind Pharm; 2011 Sep; 37(9):1090-9. PubMed ID: 21401343
[TBL] [Abstract][Full Text] [Related]
17. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
Destée A; Rérat K; Bourdeix I
Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
[TBL] [Abstract][Full Text] [Related]
18. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
19. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
20. LC determination of entacapone in tablets: in vitro dissolution studies.
Paim CS; Martins MT; Malesuik MD; Steppe M
J Chromatogr Sci; 2010 Oct; 48(9):755-9. PubMed ID: 20875238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
